BioPharma Credit PLC (LSE:BPCR) — Market Cap & Net Worth
Market Cap & Net Worth: BioPharma Credit PLC (BPCR)
BioPharma Credit PLC (LSE:BPCR) has a market capitalization of $1.09 Billion ($1.09 Billion) as of September 16, 2026. Listed on the LSE stock exchange, this UK-based company holds position #8535 globally and #30 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioPharma Credit PLC's stock price $0.97 by its total outstanding shares 1129227778 (1.13 Billion). Also see BPCR asset base for a full breakdown of the balance sheet.
BioPharma Credit PLC Market Cap History: 2017 to 2026
BioPharma Credit PLC's market capitalization history from 2017 to 2026. Data shows growth from $611.25 Million to $1.09 Billion (6.68% CAGR). Also see BPCR cash flow metrics for how efficiently the company converts equity into cash flow.
BioPharma Credit PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioPharma Credit PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BPCR stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.02x
BioPharma Credit PLC's market cap is 8.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.17x
BioPharma Credit PLC's market cap is 8.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $611.25 Million | $33.65 Million | $27.16 Million | 18.17x | 22.50x |
| 2018 | $671.21 Million | $78.72 Million | $70.15 Million | 8.53x | 9.57x |
| 2019 | $689.28 Million | $124.12 Million | $122.33 Million | 5.55x | 5.63x |
| 2020 | $731.74 Million | $91.35 Million | $89.14 Million | 8.01x | 8.21x |
| 2021 | $766.86 Million | $87.97 Million | $84.96 Million | 8.72x | 9.03x |
| 2022 | $849.74 Million | $184.25 Million | $182.31 Million | 4.61x | 4.66x |
| 2023 | $845.45 Million | $159.68 Million | $108.45 Million | 5.29x | 7.80x |
| 2024 | $998.24 Million | $124.46 Million | $122.18 Million | 8.02x | 8.17x |
Competitor Companies of BPCR by Market Capitalization
Companies near BioPharma Credit PLC in the global market cap rankings as of September 16, 2026. Review BioPharma Credit PLC (BPCR) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BioPharma Credit PLC by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #144 globally with a market cap of $165.42 Billion USD.
- Blackstone Group Inc (NYSE:BX): Ranked #270 globally with a market cap of $96.55 Billion USD.
- KKR & Co. Inc. (NYSE:KKR): Ranked #289 globally with a market cap of $91.80 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #314 globally with a market cap of $84.90 Billion USD ( CA$117.36 Billion CAD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #144 | BlackRock Inc | NYSE:BLK | $165.42 Billion | $1065.60 |
| #270 | Blackstone Group Inc | NYSE:BX | $96.55 Billion | $128.29 |
| #289 | KKR & Co. Inc. | NYSE:KKR | $91.80 Billion | $102.27 |
| #314 | Brookfield Corporation | TO:BN | $84.90 Billion | CA$52.29 |
BioPharma Credit PLC Historical Marketcap From 2017 to 2026
Between 2017 and today, BioPharma Credit PLC's market cap moved from $611.25 Million to $ 1.09 Billion, with a yearly change of 6.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.09 Billion | +5.46% |
| 2025 | $1.03 Billion | +3.62% |
| 2024 | $998.24 Million | +18.07% |
| 2023 | $845.45 Million | -0.50% |
| 2022 | $849.74 Million | +10.81% |
| 2021 | $766.86 Million | +4.80% |
| 2020 | $731.74 Million | +6.16% |
| 2019 | $689.28 Million | +2.69% |
| 2018 | $671.21 Million | +9.81% |
| 2017 | $611.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of BioPharma Credit PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.09 Billion USD |
| MoneyControl | $1.09 Billion USD |
| MarketWatch | $1.09 Billion USD |
| marketcap.company | $1.09 Billion USD |
| Reuters | $1.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.